9-valent HPV Vaccine in Postpartum Women

NCT04311528 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-03-17

No results posted yet for this study

Summary

This study will evaluate the immunogenicity of the 9-valent HPV vaccine in post-partum women age 16-45.

Conditions

Interventions

BIOLOGICAL

9-valent HPV vaccine

9-valent HPV vaccine

Sponsors & Collaborators

  • Augusta University

    lead OTHER

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2021-12-31
Completion
2021-12-31
FDA Drug
Yes

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04311528 on ClinicalTrials.gov